Lupin gets U.S. FDA nod for generic of Takeda's constipation drug
Prucalopride Tablets are bioequivalent to Motegrity Tablets 1 mg and 2 mg of Takeda Pharmaceuticals U.S.A. Inc, Lupin said on U.S. FDA approving its abbreviated new drug application.
Lupin will manufacture the product at its Goa facility. Prucalopride Tablets 1 mg and 2 mg (reference listed drug Motegrity) had estimated annual sales of $184 million in the U.S, the company said citing IQVIA MAT April 2025 numbers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 days ago
- The Hindu
Sandoz to market Lupin's biosimilar ranibizumab in multiple markets globally
Lupin on Tuesday announced a partnership with Swiss major Sandoz Group AG to market and commercialise its biosimilar ranibizumab across multiple regions. Sandoz will oversee commercialisation of the product across European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam and Malaysia. Lupin will be responsible for manufacturing the product and for regulatory submissions. Ranibizumab is indicated in treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR) and Choroidal Neovascularization (CNV). Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights. It will also acquire sole rights for commercialisation of the biosimilar in Canada, while Lupin will manage the manufacture and regulatory filings.
Business Standard
2 days ago
- Business Standard
Lupin joins hands with Sandoz to commercialize biosimilar Ranibizumab across multiple regions
Lupin has announced a strategic partnership with Switzerland-based Sandoz Group AG (Sandoz) to market and commercialize its biosimilar ranibizumab across multiple regions. Under the agreement, Sandoz will handle commercialization of the biosimilar across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will be responsible for manufacturing the product and managing regulatory submissions. In most designated markets, Sandoz will have exclusive marketing rights, while in France, Australia, Vietnam, and Malaysia, the rights will be semi-exclusive. Additionally, through a separate agreement, Sandoz will acquire sole commercialization rights for Lupins biosimilar ranibizumab in Canada, with Lupin continuing to manage manufacturing and regulatory filings. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularization (CNV). Thierry Volle, President EMEA and Emerging Markets, Lupin, said, We are delighted to partner with Sandoz for the launch and commercialization of ranibizumab in multiple markets globally. This partnership underscores our shared vision to expand global access to cutting-edge biologic therapies and improve outcomes for underserved patients. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupins consolidated net profit jumped 52.13% to Rs 1,219.03 crore on 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25. The counter rose 0.45% to Rs 1,955 on the BSE.
Business Standard
2 days ago
- Business Standard
Lupin partners with Sandoz for launch and commercialization of ranibizumab across global markets
Lupin today announced that it has partnered with Sandoz Group AG (Sandoz), Switzerland, to market and commercialize Lupin's biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will be responsible for manufacturing the product and for regulatory submissions. Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights. Pursuant to another agreement executed between the two companies, Sandoz will acquire sole rights for commercialization of Lupin's biosimilar ranibizumab in Canada, while Lupin will manage its manufacture and regulatory filings. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularization (CNV).
